Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:2.7.11.1 (protein kinase)
81,284 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The c-mos proto-oncogene exists as a maternal mRNA in mammalian oocytes, in that it has been shown to accumulate in mouse oocytes during the growth phase and to be present at high levels in fully grown oocytes. The function of c-mos during the subsequent development of the oocytes and embryos was examined by determining the fate of the oocyte c-mos mRNAs by in situ hybridization and Northern blot hybridization analysis. A substantial decrease in the levels of c-mos transcripts was observed in oocytes undergoing meiotic maturation. By the two-cell stage, levels of c-mos transcripts dropped to below the limits of detection using in situ hybridization. c-mos transcripts remained undectable through the blastocyst stage of embryogenesis. Analysis of meiotic maturation in vitro permitted finer temporal resolution of the initial drop in c-mos levels. Between approximately 7 and 17 h of culture, the amount of c-mos mRNA fell to 18-43% of the levels found in the fully grown oocyte. This interval corresponds to the progression of meiotic maturation from metaphase I to metaphase II. Our in vivo studies showed that ovulation per se is not the stimulus for the drop in c-mos transcript levels, since preovulatory metaphase II oocytes exhibited this decline to a degree comparable to that of ovulated metaphase II oocytes. The development specificity of c-mos transcript levels suggests a role of this putative serine kinase in the meiotic maturation of mammalian germ cells.
...
PMID:Evidence for the involvement of the proto-oncogene c-mos in mammalian meiotic maturation and possibly very early embryogenesis. 284 Feb 83

The mos oncogene present in Moloney murine sarcoma virus is one of the oldest known oncogenes, yet the identification of its biochemical function both in transformation and as a cellular proto-oncogene has been elusive. Only recently have low levels of c-mos transcripts been detected in a specific group of mouse tissues. The c-mos gene is implicated in tumorigenicity by its activation by the insertion of the intracisternal A particle genome in a mouse plasmacytoma. The murine c-mos gene is capable of oncogenic transformation when placed under the regulatory control of a long terminal repeat. The acquisition of the v-mos gene generated the transformation-competent Moloney murine sarcoma virus and several related strains. Myeloproliferative sarcoma virus is unique among the v-mos containing viruses in its ability to induce splenic foci and myeloproliferation in vivo in addition to the transformation of fibroblasts. The v-mos gene product, termed p37mos, is a cytoplasmic protein recently shown to possess serine kinase activity in immune complexes. Autophosphorylation of the mos gene product is not necessary for its biological activity as exemplified by the protein HT1-MSV which lacks phosphoserine residues. A transcriptional regulatory property has been attributed to the v-mos gene product during infection, which may play an essential role in subsequent transformation.
...
PMID:Functions of the mos oncogene family and associated gene products. 294 5

Sera from rat bearing tumors induced by inoculation of FBJ murine osteogenic sarcoma virus (FBJ-MSV) nonproducer rat cells precipitate two proteins with molecular weights of 55,000 (p55) and 39,000 (p39) from FBJ-MSV-transformed cells. These proteins cannot be precipitated from uninfected cells or cells transformed by other strains of murine sarcoma virus, nor can they be precipitated by sera specific for the viral structural proteins. A methionine tryptic peptide mapping analysis showed that p55 and p39 have little or no homology and that they are not related to the helper virus gag and env gene products. p55 could also be detected among the in vitro translation products of 70S RNA from FBJ murine leukemia virus plus FBJ-MSV virions but not among those from FBJ murine leukemia virus alone. This suggests that p55 is encoded by the FBJ-MSV genome, whereas p39, which was not detected among the in vitro translation products, may not be virus encoded. Another difference between p55 and p39 is that p55 is phosphorylated, with most of the phosphate on a serine residue(s), whereas p39 is phosphorylated to a much lesser extent, if at all. No protein kinase activity was associated with p55 and p39 immune complexes under standard conditions. Our data suggest that p55 is a strong candidate for the FBJ-MSV oncogene product.
...
PMID:Candidate product of the FBJ murine osteosarcoma virus oncogene: characterization of a 55,000-dalton phosphoprotein. 628 32

A new acute transforming type C retrovirus was isolated from mice inoculated with a virus stock obtained by iododeoxyuridine induction of methylcholanthrene-transformed C3H/10T1/2 mouse cells. This virus, designated 3611-MSV, transforms embryo fibroblasts and epithelial cells in culture and induces fibrosarcomas in vivo. 3611-MSV is replication defective, requiring a type C helper virus for propagation both in vitro and in vivo. By using endpoint transmission of 3611-MSV to MMCE C17 mouse and FRE 3A rat cells, several nonproductively transformed clonal cell lines have been derived. Pseudotype virus stocks obtained from such clones transform cells in vitro, are highly oncogenic in vivo, and exhibit host range and serological properties that are characteristic of their helper virus component. Analysis of viral antigen expression in 3611-MSV-transformed cells has led to the demonstration of a 90,000-molecular-weight (Mr) polyprotein and a 75,000-Mr probable cleavage product, both containing the amino-terminal murine leukemia virus gag gene proteins p15 and p12. In contrast to gene products of many previously described mammalian transforming viruses, 3611-MSV-encoded polyproteins lack detectable protein kinase activity, and 3611-MSV-transformed cells resemble chemically transformed cell line C3H/MCA-5, from which 3611-MuLV was originally derived, in that they do not exhibit elevated levels of phosphotyrosine. By using molecular hybridization the 3611-MSV transforming gene was found to be distinct from previously described mammalian cellular oncogenic sequences, including c-ras, c-abl, c-fes, c-fms, c-sis, and c-mos.
...
PMID:New mammalian transforming retrovirus: demonstration of a polyprotein gene product. 630 Apr 62

Recently we described the isolation of c-mos (rat). The gene belongs to the family of oncogenes. Some facts render c-mos unique among the oncogenes : a) it does not contain intervening sequences and b) its expression was never detected in a large number of normal mouse tissues examined. We undertook the sequence analysis of c-mos (rat) in order to compare it to the nucleotide sequences published for c-mos (mouse), c-mos (human), c-src and bovine protein kinase. c-mos (rat) contains an open reading frame of 1017 nucleotides, coding for a polypeptide of 339 amino acids. c-mos (rat)-makes use of the same ATG that defines the N-terminus of the c-mos (human) protein. By comparing all c-mos sequences available we found sequences with high mutational rates to be confined to certain domains. This comparison, together with data on the biological activities of the cloned DNA, allowed us to tentatively define regions involved in (a) function(s) of c-mos other than transformation.
...
PMID:Complete c-mos (rat) nucleotide sequence: presence of conserved domains in c-mos proteins. 632 35

Eukaryotic cells contain genes termed proto-oncogenes (c-onc) which have the potential to transform cells in culture and induce tumours in vivo. Most of these genes have been identified by their occasional incorporation into retroviral genomes which can act as natural transducing vectors for these and perhaps other cellular genes. Cell-derived oncogenes of retroviruses (v-onc) are associated mostly with the induction of mesenchymal tumours whereas carcinoma induction is rare. One of these rare carcinoma-inducing viruses is the acutely transforming avian retrovirus MH2 (refs 3-5). Recently we and others have shown that this virus carries a novel putative oncogene, v- mil , in addition to the known oncogene v-myc. While the transforming ability of v- mil has not been directly established, we have recently discovered by hybridization analysis that v- mil is homologous to v-raf (ref. 9), the transforming gene of the murine retrovirus 3611 MSV (ref. 10). Both viruses express the mil /raf oncogene product as a gag-fusion polyprotein, while the myc oncogene of MH2 is expressed via a subgenomic mRNA. Here we report the complete nucleotide sequence of v- mil and compare it with that of v-raf. The 80% homology between the nucleotide sequences and the 94% homology between the predicted amino acid sequences of the two viral genes clearly indicate that these are the avian and murine forms of the same gene. Comparison of the two sequences with that of the human cellular homologue (T. I. Bonner et al., manuscript in preparation) indicates that v-raf has more 3' untranslated sequences while v- mil has additional sequences from two 5' exons of the cellular homologue. Although the mil /raf amino acid sequences reveal partial homology to that of the v-src product, no tyrosine-specific protein kinase activity is detected for the gag- mil and the gag-raf hybrid proteins.
...
PMID:Nucleotide sequence of avian retroviral oncogene v-mil: homologue of murine retroviral oncogene v-raf. 632 30

The c-mos proto-oncogene product, Mos, is a serine/threonine protein kinase that controls the meiotic cell cycle in vertebrate oocytes. Both in vivo and in vitro, Mos can activate mitogen-activated protein kinase (MAPK) most probably by direct phosphorylation of MAPK kinase (MAPKK). In many cell types transformed by diverse oncogene products such as Raf, MAPK is constitutively activated, suggesting that the MAPK pathway may mediate oncogenic signalling by many oncogene products. Using mouse NIH3T3 cells, we examined whether oncogenic transformation by Mos is mediated by MAPK activation. Coexpression of a kinase-defective (dominant-negative) mutant of Mek1, one of the MAPKK isoforms, completely suppressed transformation by Mos. By contrast, coexpression of wild-type Mek1 markedly enhanced the transforming efficiency of Mos. Moreover, overexpression of the dominant-negative Mek1 reverted the transformation phenotype of Mos-transformed cells. These results indicate that in NIH3T3 cells the Mek1/MAPK pathway is necessary and sufficient for transformation (and its maintenance) by Mos. Transformation of NIH3T3 cells by Raf or Ras was also suppressed by the dominant-negative Mek1, but significantly less efficiently than that by Mos, suggesting the existence of multiple signalling pathways for Raf and Ras oncoproteins.
...
PMID:MAP kinase activation is essential for oncogenic transformation of NIH3T3 cells by Mos. 770 Jun 41

In vertebrates, unfertilized eggs are arrested at second meiotic metaphase by a cytostatic factor (CSF), an essential component of which is the product of the c-mos proto-oncogene. CSF prevents ubiquitin-dependent degradation of mitotic cyclins and thus inactivation or the M phase-promoting factor (MPF). Fertilization or parthenogenetic activation triggers a transient increase in the cytoplasmic free Ca2+ (reviewed in refs 5 and 6), inactivates both CSF and MPF, and releases eggs from meiotic metaphase arrest. A calmodulin-dependent process is required for cyclin degradation to occur in cell-free extracts prepared from metaphase II-arrested eggs (CSF extracts) when the free Ca2+ concentration is transiently raised in the physiological micromolar range. Here we show that when a constitutively active mutant of calmodulin-dependent protein kinase II (CaM KII) is added to a CSF extract, cyclin degradation and Cdc2 kinase inactivation occur even in the absence of Ca2+, and the extract loses its ability to cause metaphase arrest when transferred into embryos. Furthermore, specific inhibitors of CaM KII prevent cyclin degradation after calcium addition. Finally, the direct microinjection of constitutively active CaM KII into unfertilized eggs inactivates Cdc2 kinase and CSF, even in the absence of a Ca2+ transient. The target for Ca(2+)-calmodulin is thus CaM KII.
...
PMID:Calmodulin-dependent protein kinase II mediates inactivation of MPF and CSF upon fertilization of Xenopus eggs. 823 78

The c-raf-1 proto-oncogene is the cellular homologue of v-raf, the oncogene of the acutely transforming retrovirus 3611-MSV. The product of c-raf-1 (raf-1) is a 74-kDa cytoplasmic serine/threonine protein kinase. We previously reported that antisense human c-raf-1 cDNA transfection results in reduction of the endogenous c-raf-1 transcript, decreased tumor growth rate, and enhanced radiation sensitivity of SQ-20B tumor cells established from a radiation-resistant laryngeal squamous cell carcinoma. In the study reported here, we used cDNA-linked polymerase chain reaction amplification and nucleotide sequencing to examine the structure of the 3233-bp SQ-20B c-raf-1 cDNA. The 812-bp c-raf-1 promoter region was analyzed by genomic DNA amplification followed by cloning and sequencing. Sequence comparison with a previously published c-raf-1 sequence indicated no structural changes within the coding region of SQ-20B c-raf-1. However, a 4-bp deletion was observed in the 3' untranslated region within exon 17. This deletion was also present in a c-raf-1 cDNA clone isolated from a SQ-20B cDNA library. While the possibility of a 3' transcriptional control mechanism cannot be ruled out, it appears that the raf-1 protein kinase may regulate the development of radioresistant malignancies via interaction with other molecules in the damage and repair-related signal transduction pathways.
...
PMID:Nucleotide sequence analysis of c-raf-1 cDNA and promoter from a radiation-resistant human squamous carcinoma cell line: deletion within exon 17. 835 93

During studies of the activation and inactivation of the cyclin B-p34cdc2 protein kinase (MPF) in cell-free extracts of Xenopus oocytes and eggs, we found that a bacterially expressed fusion protein between the Escherichia coli maltose-binding protein and the Xenopus c-mos protein kinase (malE-mos) activated a 42 kDa MAP kinase. The activation of MAP kinase on addition of malE-mos was consistent, whereas the activation of MPF was variable and failed to occur in some oocyte extracts in which cyclin A or okadaic acid activated both MPF and MAP kinase. In cases when MPF activation was transient, MAP kinase activity declined after MPF activity was lost, and MAP kinase, but not MPF, could be maintained at a high level by the presence of malE-mos. When intact oocytes were treated with progesterone, however, the activation of MPF and MAP kinase occurred simultaneously, in contrast to the behaviour of extracts. These observations suggest that one role of c-mos may be to maintain high MAP kinase activity in meiosis. They also imply that the activation of MPF and MAP kinase in vivo are synchronous events that normally rely on an agent that has still to be identified.
...
PMID:The c-mos proto-oncogene protein kinase turns on and maintains the activity of MAP kinase, but not MPF, in cell-free extracts of Xenopus oocytes and eggs. 838 16


<< Previous 1 2 3 4 Next >>

---